Current problems in cancer. Case reports最新文献

筛选
英文 中文
Prolonged survival in postoperative recurrent EGFR-L858R NSCLC: A 24-year case report 延长 EGFR-L858R NSCLC 术后复发患者的生存期:长达 24 年的病例报告
IF 0.2
Current problems in cancer. Case reports Pub Date : 2024-10-18 DOI: 10.1016/j.cpccr.2024.100329
Yoshihiro Go , Chinatsu Yoshizaki , Yuki Yoshida , Shiho Nohmi , Rui Kusakado , Yuichiro Saito , Kensuke Izumizaki , Takafumi Ogawa , Takashi Suzuki , Fumihiro Yamaguchi
{"title":"Prolonged survival in postoperative recurrent EGFR-L858R NSCLC: A 24-year case report","authors":"Yoshihiro Go ,&nbsp;Chinatsu Yoshizaki ,&nbsp;Yuki Yoshida ,&nbsp;Shiho Nohmi ,&nbsp;Rui Kusakado ,&nbsp;Yuichiro Saito ,&nbsp;Kensuke Izumizaki ,&nbsp;Takafumi Ogawa ,&nbsp;Takashi Suzuki ,&nbsp;Fumihiro Yamaguchi","doi":"10.1016/j.cpccr.2024.100329","DOIUrl":"10.1016/j.cpccr.2024.100329","url":null,"abstract":"<div><div>The use of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is well-established for the treatment of advanced non-small cell lung cancer (NSCLC) patients with activating <em>EGFR</em> mutations. In this study, we report the long-term efficacy of EGFR-TKI therapy in a patient with postoperative recurrent NSCLC. A 58-year-old Japanese woman experienced recurrence after surgery, and an <em>EGFR</em> L858R mutation was identified. The patient continued gefitinib therapy for over 13 years, achieving a long-term survival of 21 years after postoperative recurrence, and 24 years after the initial diagnosis. This is the first report of a long-term response to EGFR-TKI therapy in an NSCLC patient with an L858R mutation. This case suggests the potential effectiveness of combining local therapy with EGFR-TKI treatment for metachronous oligometastatic disease.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"16 ","pages":"Article 100329"},"PeriodicalIF":0.2,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142534539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refractory chronic lymphocytic leukemia with concomitant extramedullary multiple myeloma with lymph node involvement 难治性慢性淋巴细胞白血病合并淋巴结受累的髓外多发性骨髓瘤
IF 0.2
Current problems in cancer. Case reports Pub Date : 2024-10-18 DOI: 10.1016/j.cpccr.2024.100324
Piotr Jachimowski , Łukasz Ciulkiewicz , Bogna Ziarkiewicz-Wróblewska , Laretta Grabowska-Derlatka , Grzegorz Basak , Mateusz Ziarkiewicz
{"title":"Refractory chronic lymphocytic leukemia with concomitant extramedullary multiple myeloma with lymph node involvement","authors":"Piotr Jachimowski ,&nbsp;Łukasz Ciulkiewicz ,&nbsp;Bogna Ziarkiewicz-Wróblewska ,&nbsp;Laretta Grabowska-Derlatka ,&nbsp;Grzegorz Basak ,&nbsp;Mateusz Ziarkiewicz","doi":"10.1016/j.cpccr.2024.100324","DOIUrl":"10.1016/j.cpccr.2024.100324","url":null,"abstract":"<div><div>Concomitant chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) in the same patient is extremely rare. In this report, we present an unprecedented case of a patient with a history of progressive, purine analog-resistant CLL, who developed extramedullary malignant plasmacytic infiltrates in lymph nodes on the background of preexisting CLL lesions, presenting with clinical sequelae attributable to active MM (hypercalcemia, renal insufficiency, anemia, bone lesions). We administered R-CHOP with bortezomib with partial remission and both CLL and MM relapsed after one month. Our patient deceased three months later. Surprisingly first bone marrow trephine biopsy did not reveal plasmacytic infiltration. However combination of symptoms presented by our patient should always be an indication for repeating biopsy. Early detection of aggressive multiple myeloma can improve prognosis and prolong survival.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"16 ","pages":"Article 100324"},"PeriodicalIF":0.2,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142534540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report 化疗当天服用非格司亭预防药物引发过敏性休克:病例报告
IF 0.2
Current problems in cancer. Case reports Pub Date : 2024-10-17 DOI: 10.1016/j.cpccr.2024.100328
Suluck Soontaros , Supaporn Wongduang , Nattawut Leelakanok
{"title":"Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report","authors":"Suluck Soontaros ,&nbsp;Supaporn Wongduang ,&nbsp;Nattawut Leelakanok","doi":"10.1016/j.cpccr.2024.100328","DOIUrl":"10.1016/j.cpccr.2024.100328","url":null,"abstract":"<div><h3>Introduction</h3><div>Filgrastim is recommended to be used 24–72 h after the last dose of chemotherapy for the prophylaxis of febrile neutropenia. However, several studies demonstrate the efficacy and safety of the use of filgrastim within the same day of the last dose of chemotherapy.</div></div><div><h3>Case presentation</h3><div>We presented a patient with state IIIC immature teratoma at her right ovary who was treated with the BEP regimen. She received 10 doses of filgrastim per BEP cycle to prevent febrile neutropenia. On the first BEP cycle, the first dose of filgrastim was used within 24 h after the last chemotherapy dose and dyspnea was developed. On the second cycle of BEP, filgrastim was still used as the same-day regimen. One hour after the first dose of filgrastim, anaphylaxis occurred and the patient was treated appropriately. The second dose of filgrastim can be rechallenged successfully and filgrastim can be finished without any adverse events. On the third and fourth cycles of BEP, filgrastim was used as the next-day regimen (interval longer than 24 h). There were no adverse events that occurred during the use of filgrastim.</div></div><div><h3>Conclusion</h3><div>The residual chemotherapy may increase the risk of anaphylaxis induced by filgrastim via a non-IgE-mediated mechanism in this case patient.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"16 ","pages":"Article 100328"},"PeriodicalIF":0.2,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142534679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refractory IgM AL amyloidosis with massive soft tissue tumors: Rescue with zanubrutinib. A case report 难治性IgM AL淀粉样变性伴巨大软组织肿瘤:扎努布替尼的救治。病例报告
IF 0.2
Current problems in cancer. Case reports Pub Date : 2024-10-12 DOI: 10.1016/j.cpccr.2024.100325
Piotr Jachimowski , Łukasz Ciulkiewicz , Mateusz Ziarkiewicz , Bogna Ziarkiewicz-Wróblewska , Marta Legatowicz-Koprowska , Krzysztof Jamroziak
{"title":"Refractory IgM AL amyloidosis with massive soft tissue tumors: Rescue with zanubrutinib. A case report","authors":"Piotr Jachimowski ,&nbsp;Łukasz Ciulkiewicz ,&nbsp;Mateusz Ziarkiewicz ,&nbsp;Bogna Ziarkiewicz-Wróblewska ,&nbsp;Marta Legatowicz-Koprowska ,&nbsp;Krzysztof Jamroziak","doi":"10.1016/j.cpccr.2024.100325","DOIUrl":"10.1016/j.cpccr.2024.100325","url":null,"abstract":"<div><div>Waldenström macroglobulinemia (WM) is a rare indolent B-cell non-Hodgkin lymphoma with lymphoplasmacytic morphology, associated with immunoglobulin M (IgM) monoclonal gammopathy. The coexistence of WM and immunoglobulin light chain (AL) amyloidosis is an uncommon but well-described phenomenon. In patients suffering from IgM AL amyloidosis soft tissue involvement and neuropathy are more prevalent in comparison to non-IgM patients. We present a case of 82-year old female with WM and intercurrent IgM AL amyloidosis, presenting with massive amyloidomas of both lower extremities, without significant cardiac and renal involvement. The patient was refractory to several lines of treatment and finally started on zanubrutinib monotherapy, with rapid and sustained very good partial hematologic response (VGPR) and clinical improvement.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"16 ","pages":"Article 100325"},"PeriodicalIF":0.2,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142441479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unusual presentation of melena due to duodenal metastasis from primary lung adenocarcinoma 原发性肺腺癌十二指肠转移引起的血性腹泻的异常表现
IF 0.2
Current problems in cancer. Case reports Pub Date : 2024-10-11 DOI: 10.1016/j.cpccr.2024.100326
Gülden Bilican , Serkan Dumanlı , Ercan Yıldırım , Ali Karataş , Ayşenur Sert , Ozan Yazıcı
{"title":"Unusual presentation of melena due to duodenal metastasis from primary lung adenocarcinoma","authors":"Gülden Bilican ,&nbsp;Serkan Dumanlı ,&nbsp;Ercan Yıldırım ,&nbsp;Ali Karataş ,&nbsp;Ayşenur Sert ,&nbsp;Ozan Yazıcı","doi":"10.1016/j.cpccr.2024.100326","DOIUrl":"10.1016/j.cpccr.2024.100326","url":null,"abstract":"<div><div>We present a rare case of duodenal metastasis from primary lung adenocarcinoma, emphasizing the diagnostic challenges and treatment considerations associated with this uncommon metastatic presentation. Through this case report, we aim to enhance awareness of this clinical entity and highlight the importance of multidisciplinary collaboration in its management.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"16 ","pages":"Article 100326"},"PeriodicalIF":0.2,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142534535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Definitive chemoradiotherapy with Carboplatin Plus Paclitaxel for Unresectable Locally Advanced Thymic Carcinoma: A case series 用卡铂加紫杉醇对无法切除的局部晚期胸腺癌进行确定性化放疗:一个病例系列
IF 0.2
Current problems in cancer. Case reports Pub Date : 2024-09-17 DOI: 10.1016/j.cpccr.2024.100323
Koichiro Nozaki, Satoshi Watanabe, Ryo Yamazaki, Masashi Arita, Toshiaki Kikuchi
{"title":"Definitive chemoradiotherapy with Carboplatin Plus Paclitaxel for Unresectable Locally Advanced Thymic Carcinoma: A case series","authors":"Koichiro Nozaki,&nbsp;Satoshi Watanabe,&nbsp;Ryo Yamazaki,&nbsp;Masashi Arita,&nbsp;Toshiaki Kikuchi","doi":"10.1016/j.cpccr.2024.100323","DOIUrl":"10.1016/j.cpccr.2024.100323","url":null,"abstract":"<div><h3>Objectives</h3><p>Thymic carcinoma (TC) is rare. There is no evidence regarding the treatment strategies for unresectable locally advanced thymic carcinomas. Definitive chemoradiotherapy may treat this condition. However, an appropriate concurrent chemotherapy with radiotherapy has not yet been established.</p></div><div><h3>Materials and methods</h3><p>We present three cases of locally advanced thymic carcinoma treated with definitive chemoradiotherapy using carboplatin and paclitaxel.</p></div><div><h3>Results</h3><p>Three patients aged 74–81 with Masaoka stage III thymic carcinoma were included. One patient was a woman, and two patients were men. All patients received weekly carboplatin (area under the curve, 2) plus paclitaxel (40 mg m<sup>-12</sup>) and concurrent radiotherapy (60 Gy). One patient experienced an adverse event of grade 3 radiation pneumonitis after chemoradiotherapy, but the three patients completed chemoradiotherapy with minor adverse events during treatment. Progression-free survival after chemoradiotherapy was 59+, 24+, and 16+ months, respectively; all patients were alive.</p></div><div><h3>Conclusion</h3><p>Definitive concurrent chemoradiotherapy with weekly carboplatin plus paclitaxel may be effective for treating unresectable locally advanced thymic carcinomas.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"16 ","pages":"Article 100323"},"PeriodicalIF":0.2,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000462/pdfft?md5=fa9d2b295942b0387d1f7cb0dacef82f&pid=1-s2.0-S2666621924000462-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142272642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of anamorelin hydrochloride in a patient with lung cancer-related cachexia undergoing chemoradiotherapy: A case report 在接受化疗放疗的肺癌相关恶病质患者中使用盐酸阿那莫林:病例报告
IF 0.2
Current problems in cancer. Case reports Pub Date : 2024-09-12 DOI: 10.1016/j.cpccr.2024.100322
Haruka Fujioka , Kei Nakashima , Nana Munakata , Shigenori Yamamoto , Reina Idemitsu , Taiki Kawai , Kentaro Tochigi , Yasuhiro Morimoto , Hiroyuki Ito , Ayumu Otsuki
{"title":"Use of anamorelin hydrochloride in a patient with lung cancer-related cachexia undergoing chemoradiotherapy: A case report","authors":"Haruka Fujioka ,&nbsp;Kei Nakashima ,&nbsp;Nana Munakata ,&nbsp;Shigenori Yamamoto ,&nbsp;Reina Idemitsu ,&nbsp;Taiki Kawai ,&nbsp;Kentaro Tochigi ,&nbsp;Yasuhiro Morimoto ,&nbsp;Hiroyuki Ito ,&nbsp;Ayumu Otsuki","doi":"10.1016/j.cpccr.2024.100322","DOIUrl":"10.1016/j.cpccr.2024.100322","url":null,"abstract":"<div><p>This report describes the case of a 59-year-old man with poorly differentiated lung adenocarcinoma and cachexia who completed chemoradiation therapy for stage III lung cancer following the administration of anamorelin. Anamorelin, a ghrelin receptor agonist, effectively improved his appetite and performance status, thereby enabling the continuation of treatment. The role of anamorelin in enhancing appetite during acute-phase treatment is promising; however, further studies must be conducted to elucidate its interaction with chemoradiation therapy. This case report highlights the potential of anamorelin as a therapeutic option for the management of cancer-related cachexia during curative treatment for lung cancer.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"16 ","pages":"Article 100322"},"PeriodicalIF":0.2,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000450/pdfft?md5=863f25a88439439e21d5e29ef2a90d24&pid=1-s2.0-S2666621924000450-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142272641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stauffer syndrome in a tumor of the pancreatic tail: A paracrine pathogenesis, rather than an inflammatory disimmune phenomenon – a case report 胰腺尾部肿瘤引发的 Stauffer 综合征:旁分泌型发病机制,而非炎症性免疫失调现象--病例报告
IF 0.2
Current problems in cancer. Case reports Pub Date : 2024-09-01 DOI: 10.1016/j.cpccr.2024.100320
Caterina Porciani , Piero Colombatto , Simone Guadagni , Gabriele Ricco , Luca Morelli , Laura Caponi , Daniela Campani , Annalisa Comandatore , Giusi Desire' Sciume' , Paola Migliorini , Piero Boraschi , Maurizia Brunetto , Giulio Di Candio
{"title":"Stauffer syndrome in a tumor of the pancreatic tail: A paracrine pathogenesis, rather than an inflammatory disimmune phenomenon – a case report","authors":"Caterina Porciani ,&nbsp;Piero Colombatto ,&nbsp;Simone Guadagni ,&nbsp;Gabriele Ricco ,&nbsp;Luca Morelli ,&nbsp;Laura Caponi ,&nbsp;Daniela Campani ,&nbsp;Annalisa Comandatore ,&nbsp;Giusi Desire' Sciume' ,&nbsp;Paola Migliorini ,&nbsp;Piero Boraschi ,&nbsp;Maurizia Brunetto ,&nbsp;Giulio Di Candio","doi":"10.1016/j.cpccr.2024.100320","DOIUrl":"10.1016/j.cpccr.2024.100320","url":null,"abstract":"<div><p>Stauffer syndrome, also known as paraneoplastic intrahepatic cholestasis syndrome, is a rare reversible clinical manifestation characterized by elevation of direct bilirubin, alcaline phosphatase, transaminases and prolonged prothrombin time, without direct hepatobiliary disease, that is due to the presence of malignancy, mostly kidney cancer. In this case report, we describe a rare form of mixed acinar neuroendocrine pancreatic tail mass causing a non-obstructive form of cholestasis. We analysed the effects of metilprednisolone treatment and surgery on the levels of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF alpha), previously associated with this syndrome. We found that serum levels of IL-6 and TNF alpha decreased during steroid treatment, had a peak immediately after the surgical procedure, and remained stable while cholestasis resolved slowly after tumour removal. These findings showed that IL-6 and TNF alpha were not the effectors of the paraneoplastic cholestasis in our patient. Rather, the evidence of a mixed acinar neuroendocrine pancreatic tumour and non-specific cholestasis at the liver histology suggests paracrine mechanisms affecting cellular transporters implicated in bile acids excretion.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"15 ","pages":"Article 100320"},"PeriodicalIF":0.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000437/pdfft?md5=abb1c6a23eb67343a69b75ff773faa98&pid=1-s2.0-S2666621924000437-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142136275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case report: Heterogeneity in the primary lesions of invasive micropapillary breast carcinoma 病例报告:浸润性微乳头状瘤原发病灶的异质性
IF 0.2
Current problems in cancer. Case reports Pub Date : 2024-09-01 DOI: 10.1016/j.cpccr.2024.100321
Yang Fu , Junwei Cui , Jinming Zhou , Fang Li , Jinsong He , Zijian Yang
{"title":"Case report: Heterogeneity in the primary lesions of invasive micropapillary breast carcinoma","authors":"Yang Fu ,&nbsp;Junwei Cui ,&nbsp;Jinming Zhou ,&nbsp;Fang Li ,&nbsp;Jinsong He ,&nbsp;Zijian Yang","doi":"10.1016/j.cpccr.2024.100321","DOIUrl":"10.1016/j.cpccr.2024.100321","url":null,"abstract":"<div><p>Breast cancer (BC) is a complex and heterogeneous disease including different biological subtypes. This results in molecular and phenotypic heterogeneity within the BC. Stratification of tumors contributed to achieving better outcome in terms of response to therapy and overall survival. Little is known about the features of clonal heterogeneity in different lesion in BC patient. We reported a case of a 52-year-old woman who was diagnosed with luminal B (HER2−) BC and accepted chemotherapy. She achieved partial response based on RECIST 1.1 criteria. However, progressive disease (PD) was then identified with multiple subtypes including luminal B and triple-negative breast cancer (TNBC). Next-generation sequencing (NGS) technologies showed that the different regions of diseased tissue were originated from same clonal genes. We also demonstrated the clonal heterogeneity and gene characterization between lesions of luminal B and TNBC. The patient archived complete remission (CR) with a clear beneficial outcome from immunotherapy treatment. In addition, tumour mutational burden (TMB) and DNA damage repair (DDR) pathway were considered as potential biomarkers for better prediction of tumor immunotherapy efficacy.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"16 ","pages":"Article 100321"},"PeriodicalIF":0.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000449/pdfft?md5=1b67e5f28be621e38928eedac89505fc&pid=1-s2.0-S2666621924000449-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142241534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-flow nasal cannula combined with intravenous general anesthesia for stent implantation in right lung cancer: A case report 高流量鼻插管联合静脉全身麻醉用于右肺癌支架植入术:病例报告
IF 0.2
Current problems in cancer. Case reports Pub Date : 2024-08-14 DOI: 10.1016/j.cpccr.2024.100319
Hai-Yu Xie , Yi Li , Jiao Mo , Zhi-Yong Wu , Zhi-Min Hu , Wei-Dong Liang , Li-Feng Wang
{"title":"High-flow nasal cannula combined with intravenous general anesthesia for stent implantation in right lung cancer: A case report","authors":"Hai-Yu Xie ,&nbsp;Yi Li ,&nbsp;Jiao Mo ,&nbsp;Zhi-Yong Wu ,&nbsp;Zhi-Min Hu ,&nbsp;Wei-Dong Liang ,&nbsp;Li-Feng Wang","doi":"10.1016/j.cpccr.2024.100319","DOIUrl":"10.1016/j.cpccr.2024.100319","url":null,"abstract":"<div><p>Airway blockage frequently occurs in advanced lung cancer patients, leading to breathing difficulties and oxygen deprivation. This severely impacts patients' quality of life and can even result in death. Bronchial stent insertion effectively alleviates these symptoms and is often performed with intravenous general anesthesia. Nevertheless, during anesthesia and the procedure, inadequate ventilation can lead to severe oxygen deficiency and subsequent complications. There is an urgent need for a safe and efficient intraoperative ventilation strategy to maintain sufficient oxygen levels and reduce the risk of oxygen deficiency. We present a case of successful bronchial stent placement using high-flow nasal cannula (HFNC) in conjunction with intravenous general anesthesia. The patient, a 64-year-old male with a one-year history of right peripheral lung cancer, sought treatment for persistent cough and breathing difficulties. Chest X-rays upon admission revealed a substantial increase in the size of the anterior segment of the right upper lung lobe, likely due to peripheral lung cancer complicated by obstructive pneumonia. To address the patient's airway compression symptoms, we proposed \"bronchoscopic tracheal stent insertion.\" The patient exhibited an ejection fraction of 45% on cardiac ultrasound, had limited physical activity tolerance, grade III heart function, severe airway constriction, and maintained oxygen saturation (SPO<sub>2</sub>) levels between 85% and 88%. We successfully performed the procedure using HFNC in combination with intravenous general anesthesia, resulting in a significant improvement in airway compression symptoms. In this case, it was found that HFNC could be used as a new non-invasive respiratory support therapy for bronchial stent implantation under intravenous general anesthesia to reduce the occurrence of intraoperative hypoxemia.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"15 ","pages":"Article 100319"},"PeriodicalIF":0.2,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000425/pdfft?md5=7d6234bff30fbabb67ea1b8c3511111e&pid=1-s2.0-S2666621924000425-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141998328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信